J
Jung-Min Lee
Researcher at National Institutes of Health
Publications - 90
Citations - 3538
Jung-Min Lee is an academic researcher from National Institutes of Health. The author has contributed to research in topics: Olaparib & PARP inhibitor. The author has an hindex of 23, co-authored 69 publications receiving 2431 citations. Previous affiliations of Jung-Min Lee include Philips.
Papers
More filters
Journal ArticleDOI
The MAPK pathway across different malignancies: a new perspective.
TL;DR: Understanding the differential nature of activation of the MAPK/ERK pathway in each tumor type is critical in developing single and combination regimens, because different tumors have unique mechanisms of primary and secondary signaling and subsequent sensitivity to drugs.
Journal ArticleDOI
Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study
Joyce F. Liu,William T. Barry,Michael J. Birrer,Jung-Min Lee,Ronald J. Buckanovich,Gini F. Fleming,Bobbie J. Rimel,Mary K. Buss,Sreenivasa Nattam,Jean A. Hurteau,Weixiu Luo,Philippa Quy,Christin Whalen,Lisa Obermayer,Hang Lee,Eric P. Winer,Elise C. Kohn,S. Percy Ivy,Ursula A. Matulonis +18 more
TL;DR: Cediranib plus olaparib seems to improve PFS in women with recurrent platinum-sensitive high-grade serous or endometrioid ovarian cancer, and warrants study in a phase 3 trial.
Journal ArticleDOI
Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations
Fatima Karzai,David J. VanderWeele,Ravi A. Madan,Helen Owens,Lisa M. Cordes,Amy Hankin,Anna Couvillon,Erin Nichols,Marijo Bilusic,Michael L. Beshiri,Kathleen Kelly,Venkatesh Krishnasamy,Sunmin Lee,Min-Jung Lee,Akira Yuno,Jane B. Trepel,Maria J. Merino,Ryan Dittamore,Jennifer L. Marte,Renee N. Donahue,Jeffrey Schlom,Keith Killian,Paul S. Meltzer,Seth M. Steinberg,James L. Gulley,Jung-Min Lee,William L. Dahut +26 more
TL;DR: Durvalumab plus olaparib has acceptable toxicity, and the combination demonstrates efficacy, particularly in men with DNA damage repair (DDR) mutations treated with checkpoint inhibitors.
Journal ArticleDOI
Tumour-elicited neutrophils engage mitochondrial metabolism to circumvent nutrient limitations and maintain immune suppression
Christopher M. Rice,Luke C. Davies,Jeff J. Subleski,Nunziata Maio,Marieli Gonzalez-Cotto,Caroline Andrews,Nimit L. Patel,Erika M. Palmieri,Jonathan M. Weiss,Jung-Min Lee,Christina M. Annunziata,Tracey A. Rouault,Scott K. Durum,Daniel W. McVicar +13 more
TL;DR: It is shown that tumours promote neutrophils adapted to oxidative mitochondria metabolism that function in the glucose-restrained tumour microenvironment to promote tumour growth by maintaining local immune suppression.
Journal ArticleDOI
Phase I/Ib Study of Olaparib and Carboplatin in BRCA1 or BRCA2 Mutation-Associated Breast or Ovarian Cancer With Biomarker Analyses
Jung-Min Lee,John L. Hays,Christina M. Annunziata,Anne M. Noonan,Lori M. Minasian,Jo Anne Zujewski,Minshu Yu,Nicolas Gordon,Jiuping Ji,Tristan M. Sissung,William D. Figg,Nilofer S. Azad,Bradford J. Wood,James H. Doroshow,Elise C. Kohn +14 more
TL;DR: Olaparib capsules 400mg every 12 hours on days 1 to 7/carboplatin AUC5 is safe and has activity in gBRCAm BrCa/OvCa patients, and proteomic analysis suggests high pretreatment pS209-eIF4E and FOXO3a correlated with duration of response.